People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

David Cortez, PhD, has been named associate director for Basic Science Research at Vanderbilt-Ingram Cancer Center (VICC).

More than a dozen representatives of Vanderbilt University Medical Center helped plan and made a commitment to help carry out the strategy for how Tennessee will prevent cancer and minimize its burden on state residents.

A team of Vanderbilt researchers constructed polygenic risk scores (PRS) based on genomic variants associated with eight common cancers and concluded they could potentially be used for personalized risk assessments.

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.

Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.